Bryan Roberts, Ph.D. joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other companies, including Ariosa Diagnostics, Doctor on Demand, Grand Rounds, Intarcia, Kyruus, and Zeltiq (NASDAQ: ZLTQ). Past investments include athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.